Formulation optimisation of an mRNA-lipid nanoparticle platform sustains in vivo production of the SARS-CoV-2-neutralizing nanobody VHH 72

Pathology - Research and Practice · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles